Table 3 Therapy, follow-up and administration costs [9, 43,44,45,46,47,48,49,50]
Treatment and posology | Ex-factory price (€) per packa | Annual monitoring costs, Year 1 (€) | Annual monitoring costs, subsequent years (€) | Annual administration costs (€) | Source of ex-factory price |
|---|---|---|---|---|---|
Natalizumab – Tysabri, 300 mg, Q4W | 1800.00 | 1104.69 | 421.42 | 589.78 | Gazette 292, 2006 [9] Gazette 139, 2014 [43] |
IFN beta 1a - Rebif 44 mcg 44mcg, tiw | 1027.75 | 1084.04 | 399.22 | 0.00 | Gazette 196, 2009 [44] Gazette 274, 2011 [45] |
IFN beta 1b – Betaferon, 250 mcg dieb. alt. | 856.01 | 1084.04 | 399.22 | 0.00 | Gazette 127, 2000 [46] Gazette 279, 2007 [47] |
Glatiramer acetate – Copaxone, 20 mg, od | 769.30 | 932.51 | 313.18 | 0.00 | Gazette 106, 2005 [48] |
IFN beta 1a – Avonex, 30 mcg, QW | 790.17 | 1084.04 | 399.22 | 0.00 | Gazette 11, 2004 [49] Gazette 272, 2011 [50] |